{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T17:41:03Z","timestamp":1786729263341,"version":"build-2736575974"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":429,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7222143"],"award-info":[{"award-number":["7222143"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National High-Level Hospital Clinical Research Funding","award":["2022-GSP-GG-9"],"award-info":[{"award-number":["2022-GSP-GG-9"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2020-I2M-1-002"],"award-info":[{"award-number":["2020-I2M-1-002"]}]},{"name":"Key Projects in the National Science and Technology Pillar Program of the 13th Five-Year Plan Period","award":["2017YFC1308300"],"award-info":[{"award-number":["2017YFC1308300"]}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7222143"],"award-info":[{"award-number":["7222143"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Heart failure (HF) with supranormal ejection fraction (HFsnEF) represents a distinct clinical entity characterized by limited treatment options and an unfavourable prognosis. Revealing its phenotypic diversity is crucial for understanding disease mechanism and optimizing patient management. We aim to identify phenotypic subgroups in HFsnEF using unsupervised clustering analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Consecutive hospitalized patients with a diagnosis of HF and a left ventricular ejection fraction \u226565% at baseline echocardiographic evaluations were included for analysis. We conducted unsupervised hierarchical clustering analysis on principal components (HCPC) to identify HFsnEF phenogroups using mixed data variables including demographics, HF duration, vital signs, anthropometrics, smoking\/drinking status, HF aetiology, comorbid diseases, laboratory tests and echocardiographic parameters. We then employed decision tree modelling to identify parameters capable of distinguishing distinct clusters. Clinical outcomes, including all-cause death, cardiovascular (CV) death and CV readmission for different clusters, were examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Three mutually exclusive clusters were identified from the cohort of 221 HFsnEF patients. Cluster 1 (52.5%) predominantly consisted of patients with valvular heart disease, who had larger cardiac chambers and a higher prevalence of atrial fibrillation\/atrial flutter. Cluster 2 (26.2%) primarily comprised older ischaemic patients with a higher prevalence of metabolic comorbidities. Cluster 3 (21.3%) were mainly hypertrophic cardiomyopathy patients. Two clinical variables were identified that could be used to group all HFsnEF patients into one of the clusters; they were HF aetiology and comorbid diabetes. During the median follow-up of 53.4 months, 46 (20.8%) all-cause deaths occurred, among them 39 of CV causes. Seventy (31.7%) patients experienced CV readmissions. Three clusters showed distinct differences in mortality outcomes, with Cluster 1 exhibiting the highest risk of all-cause mortality [Cluster 1 vs. Cluster 2: adjusted hazard ratio (aHR) = 3.32, P = 0.022; Cluster 1 vs. Cluster 3: aHR = 3.81, P = 0.036; Cluster 2 vs. Cluster 3: aHR = 1.15, P = 0.865] and CV mortality (Cluster 1 vs. Cluster 2: aHR = 3.73, P = 0.022; Cluster 1 vs. Cluster 3: aHR = 4.27, P = 0.020; Cluster 2 vs. Cluster 3: aHR = 1.15, P = 0.870). CV readmission risk was comparable among the three clusters (Cluster 1 vs. Cluster 2: aHR = 0.82, P = 0.590; Cluster 1 vs. Cluster 3: aHR = 1.04, P = 0.900; Cluster 2 vs. Cluster 3: aHR = 1.28, P = 0.580).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In a heterogeneous HFsnEF cohort, three clusters were identified by unsupervised HCPC with distinct clinical characteristics and outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.15021","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:20:54Z","timestamp":1723508454000},"page":"4160-4171","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical Phenotypes of Heart Failure Patients with Supranormal Ejection Fraction"],"prefix":"10.1093","volume":"11","author":[{"given":"Liyan","family":"Huang","sequence":"first","affiliation":[{"name":"Heart Failure Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS and PUMC) , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Feng","sequence":"additional","affiliation":[{"name":"Heart Failure Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS and PUMC) , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Zhai","sequence":"additional","affiliation":[{"name":"Heart Failure Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS and PUMC) , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Huang","sequence":"additional","affiliation":[{"name":"Heart Failure Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS and PUMC) , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Heart Failure Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS and PUMC) , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Heart Failure Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS and PUMC) , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Heart Failure Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS and PUMC) , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,12]]},"reference":[{"key":"2026012113125469100_ehf215021-bib-0001","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1093\/eurheartj\/ehz550","article-title":"Routinely reported ejection fraction and mortality in clinical practice: Where does the nadir of risk lie?","volume":"41","author":"Wehner","year":"2020","journal-title":"Eur Heart J"},{"key":"2026012113125469100_ehf215021-bib-0002","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/ejhf.2695","article-title":"Characteristics and clinical outcomes of patients with acute heart failure with a supranormal left ventricular ejection fraction","volume":"25","author":"van Essen","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026012113125469100_ehf215021-bib-0003","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/ejhf.1772","article-title":"Relationship between left ventricular ejection fraction and cardiovascular outcomes following hospitalization for heart failure: Insights from the RELAX-AHF-2 trial","volume":"22","author":"Janwanishstaporn","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012113125469100_ehf215021-bib-0004","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1002\/ejhf.2843","article-title":"Ventricular stiffening and chamber contracture in heart failure with higher ejection fraction","volume":"25","author":"Popovic","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026012113125469100_ehf215021-bib-0005","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1161\/circulationaha.122.059280","article-title":"Characteristics of heart failure with preserved ejection fraction across the range of left ventricular ejection fraction","volume":"146","author":"Rosch","year":"2022","journal-title":"Circulation"},{"key":"2026012113125469100_ehf215021-bib-0006","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1016\/j.jacc.2021.04.070","article-title":"Classification of heart failure according to ejection fraction: JACC review topic of the week","volume":"77","author":"Lam","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026012113125469100_ehf215021-bib-0007","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.jchf.2023.03.017","article-title":"Beta-blocker use and heart failure outcomes in mildly reduced and preserved ejection fraction","volume":"11","author":"Arnold","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026012113125469100_ehf215021-bib-0008","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1002\/ejhf.1149","article-title":"Heart failure with mid-range ejection fraction in CHARM: Characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum","volume":"20","author":"Lund","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012113125469100_ehf215021-bib-0009","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/circulationaha.119.044586","article-title":"Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure","volume":"141","author":"Solomon","year":"2020","journal-title":"Circulation"},{"key":"2026012113125469100_ehf215021-bib-0010","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","article-title":"Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction","volume":"37","author":"Solomon","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012113125469100_ehf215021-bib-0011","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1093\/eurheartj\/ehab798","article-title":"Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction","volume":"43","author":"Butler","year":"2022","journal-title":"Eur Heart J"},{"key":"2026012113125469100_ehf215021-bib-0012","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2026012113125469100_ehf215021-bib-0013","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1007\/978-0-387-84858-7","volume-title":"The Elements of Statistical Learning","author":"Hastie","year":"2009","edition":"2nd"},{"key":"2026012113125469100_ehf215021-bib-0014","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1093\/eurheartj\/ehaa841","article-title":"Phenotypic clustering of dilated cardiomyopathy patients highlights important pathophysiological differences","volume":"42","author":"Verdonschot","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012113125469100_ehf215021-bib-0015","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1002\/ehf2.14368","article-title":"Heart failure with preserved ejection fraction phenogroup classification using machine learning","volume":"10","author":"Kyodo","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026012113125469100_ehf215021-bib-0016","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1161\/circulationaha.114.010637","article-title":"Phenomapping for novel classification of heart failure with preserved ejection fraction","volume":"131","author":"Shah","year":"2015","journal-title":"Circulation"},{"key":"2026012113125469100_ehf215021-bib-0017","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ahj.2022.08.009","article-title":"Machine learning to define phenotypes and outcomes of patients hospitalized for heart failure with preserved ejection fraction: Findings from ASCEND-HF","volume":"254","author":"Murray","year":"2022","journal-title":"Am Heart J"},{"key":"2026012113125469100_ehf215021-bib-0018","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1002\/ehf2.14288","article-title":"Machine learning approach to stratify complex heterogeneity of chronic heart failure: A report from the CHART-2 study","volume":"10","author":"Nakano","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026012113125469100_ehf215021-bib-0019","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/ejhf.2115","article-title":"Universal definition and classification of heart failure: A report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association","volume":"23","author":"Bozkurt","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012113125469100_ehf215021-bib-0020","first-page":"169","volume-title":"Exploratory Multivariate Analysis by Example Using R","author":"Husson","year":"2011","edition":"1st"},{"key":"2026012113125469100_ehf215021-bib-0021","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v025.i01","article-title":"FactoMineR: An R package for multivariate analysis","volume":"25","author":"L\u00ea","year":"2008","journal-title":"J Stat Softw"},{"key":"2026012113125469100_ehf215021-bib-0022","volume-title":"rpart: Recursive partitioning and regression trees","author":"Therneau","year":"2023"},{"key":"2026012113125469100_ehf215021-bib-0023","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1002\/sim.2712","article-title":"Tutorial in biostatistics: Competing risks and multi-state models","volume":"26","author":"Putter","year":"2007","journal-title":"Stat Med"},{"key":"2026012113125469100_ehf215021-bib-0024","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"2026012113125469100_ehf215021-bib-0025","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1002\/ejhf.2895","article-title":"Prevalence, characteristics and cardiovascular and non-cardiovascular outcomes in patients with heart failure with supra-normal ejection fraction: Insight from the JROADHF study","volume":"25","author":"Horiuchi","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026012113125469100_ehf215021-bib-0026","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.amjcard.2020.11.034","article-title":"Role of ischemic heart disease in major adverse renal and cardiac events among individuals with heart failure with preserved ejection fraction (from the TOPCAT trial)","volume":"142","author":"Rahimi","year":"2021","journal-title":"Am J Cardiol"},{"key":"2026012113125469100_ehf215021-bib-0027","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1001\/jamacardio.2021.1825","article-title":"Prevalence of coronary artery disease and coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction","volume":"6","author":"Rush","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026012113125469100_ehf215021-bib-0028","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1002\/ejhf.327","article-title":"Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response","volume":"17","author":"Kao","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026012113125469100_ehf215021-bib-0029","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1002\/ejhf.2169","article-title":"Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction","volume":"23","author":"Uijl","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012113125469100_ehf215021-bib-0030","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jchf.2019.09.009","article-title":"Clinical phenogroups in heart failure with preserved ejection fraction: Detailed phenotypes, prognosis, and response to spironolactone","volume":"8","author":"Cohen","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2026012113125469100_ehf215021-bib-0031","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/ejhf.1621","article-title":"Phenomapping of patients with heart failure with preserved ejection fraction using machine learning-based unsupervised cluster analysis","volume":"22","author":"Segar","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012113125469100_ehf215021-bib-0032","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1002\/ejhf.2894","article-title":"Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension","volume":"25","author":"Anker","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026012113125469100_ehf215021-bib-0033","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012113125469100_ehf215021-bib-0034","doi-asserted-by":"publisher","first-page":"4406","DOI":"10.1093\/eurheartj\/ehac481","article-title":"Dapagliflozin for heart failure according to body mass index: The DELIVER trial","volume":"43","author":"Adamson","year":"2022","journal-title":"Eur Heart J"},{"key":"2026012113125469100_ehf215021-bib-0035","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012113125469100_ehf215021-bib-0036","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"2026012113125469100_ehf215021-bib-0037","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1161\/circulationaha.121.057983","article-title":"Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: Analyses from the FIGARO-DKD trial","volume":"145","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"key":"2026012113125469100_ehf215021-bib-0038","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1001\/jama.2015.17346","article-title":"Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: A randomized clinical trial","volume":"315","author":"Kitzman","year":"2016","journal-title":"JAMA"},{"key":"2026012113125469100_ehf215021-bib-0039","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/s0140-6736(24)00469-0","article-title":"Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: A pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials","volume":"403","author":"Butler","year":"2024","journal-title":"Lancet"},{"key":"2026012113125469100_ehf215021-bib-0040","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14834","article-title":"Development of interpretable machine learning models to predict in-hospital prognosis of acute heart failure patients","author":"Tanaka","year":"2024","journal-title":"ESC Heart Fail"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/6\/4160\/64517257\/eschf_11_6_4160.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/6\/4160\/64517257\/eschf_11_6_4160.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:14:53Z","timestamp":1769019293000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/11\/6\/4160\/8269426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,12]]},"references-count":40,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,8,12]]},"published-print":{"date-parts":[[2024,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.15021","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,8,12]]},"assertion":[{"value":"2024-04-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}